Dies ist eine Übersichtsseite mit Metadaten zu dieser wissenschaftlichen Arbeit. Der vollständige Artikel ist beim Verlag verfügbar.
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
6.552
Zitationen
23
Autoren
2013
Jahr
Abstract
In patients with metastatic pancreatic adenocarcinoma, nab-paclitaxel plus gemcitabine significantly improved overall survival, progression-free survival, and response rate, but rates of peripheral neuropathy and myelosuppression were increased. (Funded by Celgene; ClinicalTrials.gov number, NCT00844649.).
Ähnliche Arbeiten
The Clavien-Dindo Classification of Surgical Complications
2009 · 11.007 Zit.
Radiomics: Images Are More than Pictures, They Are Data
2015 · 8.024 Zit.
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
2011 · 7.633 Zit.
TGF-β SIGNAL TRANSDUCTION
1998 · 7.559 Zit.
Pancreatic Cancer
2000 · 7.244 Zit.
Autoren
- Daniel D. Von Hoff
- Thomas J. Ervin
- Francis P. Arena
- E. Gabriela Chiorean
- Jeffrey R. Infante
- Malcolm J. Moore
- Thomas E. Seay
- Sergei Tjulandin
- Wen Wee
- Mansoor N. Saleh
- Marion Harris
- Michele Reni
- Scot Dowden
- Daniel A. Laheru
- Nathan Bahary
- Ramesh K. Ramanathan
- Josep Tabernero
- Manuel Hidalgo
- David Goldstein
- Eric Van Cutsem
- Xinyu Wei
- José Iglesias
- Markus F. Renschler
Institutionen
- Translational Genomics Research Institute(US)
- Florida Cancer Specialists & Research Institute(US)
- Seattle University(US)
- University of Washington(US)
- Sarah Cannon(US)
- Tennessee Oncology(US)
- Princess Margaret Hospital(NZ)
- Russian Cancer Research Center NN Blokhin(RU)
- Roswell Park Comprehensive Cancer Center(US)
- Georgia Cancer Specialists(US)
- Centro Oncológico de Galicia(ES)
- Mylan (Switzerland)(CH)
- San Raffaele University of Rome(IT)
- Sidney Kimmel Comprehensive Cancer Center(US)
- University of Pittsburgh Medical Center(US)
- Universitat Autònoma de Barcelona(ES)
- Hebron University(PS)
- Prince of Wales Hospital(AU)
- KU Leuven(BE)
- Bionomics (Australia)(AU)